Therapy of secondary leukemia

Rowe, J. M.

doi:10.1038/sj.leu.2402456

Cited by 22 publications

(17 citation statements)

References 14 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study confirmed that the achievement of CR by induction chemotherapy was a prognostic factor for a better OS. It has been reported that the CR rate associated with induction chemotherapy was low when applied to t-AML compared to de novo AML [26,27]. In our study, the CR rate was 73%, which was higher than those in previous reports (around 60%).…”

Section: Discussioncontrasting

confidence: 75%

Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients

Yokoyama¹,

Mori

Kobayashi

et al. 2010

Int J Hematol

View full text Add to dashboard Cite

The prognosis of therapy-related myelodysplastic syndrome and acute leukemia (t-MDS/AL) remains poor. We retrospectively analyzed the data of 47 patients (31 AL and 16 MDS) who were treated at our institute. Thirty-three patients received disease-adapted chemotherapy, with a response rate of 73%, while 14 received no interventions due to an indolent course, such as MDS. The median follow-up of surviving patients was 1.9 years (range 0.1-10.5) after the diagnosis of t-MDS/AL, and the estimated 3-year overall survival (OS) for all patients was 55%. Twenty-seven patients underwent allogeneic hematopoietic stem cell transplantation (HCT), and the 3-year non-relapse mortality was 17%. Twenty patients did not undergo HCT due to various reasons including advanced age or comorbidities. The 3-year OS was better in patients who received HCT than in those who did not (71 vs. 31%; p = 0.018). A multivariate analysis revealed that HCT was associated with a better OS. Although this study has several limitations, including a potential selection bias due to the retrospective nature of the analysis and a small number of patients, the results show that modern HCT may be useful for inducing long-term survival in a fraction of patients suffering from t-MDS/AL. The present findings warrant future prospective studies.

show abstract

Section: Discussioncontrasting

confidence: 75%

Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients

Yokoyama¹,

Mori

Kobayashi

et al. 2010

Int J Hematol

View full text Add to dashboard Cite

show abstract

“…Therapy-related acute myeloid leukemia (t-AML) is a term used to describe the former. 1 According to the World Health Organization (WHO), t-AML, therapy-related myelodysplastic syndrome (t-MDS), and myelodysplastic syndrome/myeloproliferative neoplasms (t-MDS/MPN) developing in patients who are exposed to cytotoxic agents are collectively classified as therapy-related myeloid neoplasms (t-MN). 2 t-AML, which accounts for about 10% of all AML diagnoses, is a well-recognized complication in patients with primary malignant or non-malignant conditions after exposure to chemotherapy, radiotherapy, or immunosuppressive therapies.…”

Section: Introductionmentioning

confidence: 99%

“…1 Secondary leukemia generally refers to leukemia developing in patients who have a history of exposure to various therapeutic agents as well as a history of antecedent myeloid stem cell disorders, such as myelodysplasia (MDS). Therapy-related acute myeloid leukemia (t-AML) is a term used to describe the former.…”

Section: Introductionmentioning

confidence: 99%

Acute myeloid leukemia developing in patients with autoimmune diseases

Ramadan

Fouad

Summa³

et al. 2011

Haematologica

View full text Add to dashboard Cite

“…In this regard, 2 previous studies reported that the management of secondary leukemia patients with t(8; 21), t(15; 17), or inversion 16 by combination chemotherapy or bone marrow transplantation resulted in improvement of prognosis to a level similar to that observed in de novo AML. 7,8 These findings suggest that the prognosis is not necessarily poor in all patients with secondary leukemia. Thus, long survival is expected in patients who show complete response to bone marrow transplantation and/or combination chemotherapy for secondary leukemia.…”

Section: Discussionmentioning

confidence: 88%

Secondary Leukemia After Chemotherapy and/or Radiotherapy for Gynecologic Neoplasia

Shimada

Saito

Okadome

et al. 2014

Int J Gynecol Cancer

View full text Add to dashboard Cite

Long survival time might be expected in patients who show complete response to bone marrow transplantation and/or combination chemotherapy for secondary leukemia. In recent years, we have aggressively used various types of anticancer drugs for the treatment of not only ovarian cancer but also uterine cervical cancer and endometrial cancer. Physicians need to keep in mind the risk of secondary leukemia in the follow-up of long-term survivors after several courses of chemotherapy and radiotherapy.

show abstract

Therapy of secondary leukemia

Cited by 22 publications

References 14 publications

Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients

Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients

Acute myeloid leukemia developing in patients with autoimmune diseases

Secondary Leukemia After Chemotherapy and/or Radiotherapy for Gynecologic Neoplasia

Contact Info

Product

Resources

About